Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 1997

View Archived Issues

Positive phase II/III results for Cortecs' Macritonin

RPR's Azmacort now available in Brazil

HemaSure stops development of SteriPath

Phase I/II results for promising compound from BioTransplant and MedImmune

Aronex extends clinical trials with Nyotran

Roche and Protein Design Labs report encouraging results from Zenapax trial

Safety, pharmacological, phase I and early phase II results for SM-10902

Cerebrovascular selectivity and vasospasmolytic action of AJ-3941

Antiinflammatory imidazolyl compounds from Searle

BMS describes angiotensin II antagonists

Novel steryl-sulfatase inhibitors for breast cancer

Antitumor nucleosides from Sankyo

NSAIDS reported by P&G

Peptide P-selectin inhibitors described by Centocor

Searle describes antiplatelet agents

ADIR discloses compounds with high affinity for human D3 receptors

HIV-1 RT inhibitors from Boehringer Ingelheim

Steroidogenesis Inhibitors initiates phase I/II trial of HIV treatment

Clinical efficacy of montelukast highlighted

Purdue Pharma licenses anticancer chimeric

Zileuton associated with antiinflammatory effects in subgroup of asthmatics

Wyeth-Ayerst and NanoSystems agree to develop new formulation of Rapamune

Suplatast shows antiinflammatory effects in mild asthma

Xoma issued U.S. patent for antifungal uses of BPI-derived products

Preclinical and clinical results reported for RP-73401

Mitsubishi/Takeda codevelop new drug for AD

Ointment formulation of BioCryst's BCX-34 enters phase II for psoriasis

Update on Onconase clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...